Zacks Research Has Pessimistic Outlook of HALO Q1 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, down from their prior forecast of $0.93. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2027 earnings at $7.49 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million.

HALO has been the topic of a number of other research reports. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Benchmark restated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Trading Up 2.0 %

Shares of HALO opened at $62.27 on Thursday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics has a 52-week low of $37.73 and a 52-week high of $65.53. The firm has a market cap of $7.67 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.42 and a beta of 1.32. The business’s fifty day moving average is $56.76 and its 200-day moving average is $54.76.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HALO. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $60,054,000. Capital World Investors acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $35,773,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock valued at $47,470,000 after acquiring an additional 581,475 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company’s stock worth $39,750,000 after purchasing an additional 524,802 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at $21,838,000. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.